From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents
Abstract
The potential consequences of a major radiological event are not only large-scale external radiation exposure of the population, but also uncontrolled dissemination of, and internal contamination with, radionuclides. When planning an emergency response to radiological and nuclear incidents, one must consider the need for not only post-exposure treatment for contaminated individuals, but also prophylactic measures to protect the workforce facing contaminated areas and patients in the aftermath of such events. In addition to meeting the desired criteria for post-exposure treatments such as safety, ease of administration, and broad-spectrum efficacy against multiple radionuclides and levels of challenge, ideal prophylactic countermeasures must include rapid onset; induce minimal to no performance-decrementing side effects; be compatible with current military Chemical, Biological, Radiological, Nuclear, and Explosive countermeasures; and require minimal logistical burdens. Hydroxypyridinone-based actinide decorporation agents have shown the most promise as decorporation strategies for various radionuclides of concern, including the actinides plutonium and americium. The studies here probe the extent of plutonium decorporation efficacy for two chelating agents, 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO), from early pre-exposure time points to a delay of up to 7 days in parenteral or oral treatment administration, i.e., well beyond the initial hours of emergency response. Despite delayed treatment after amore »
- Authors:
-
- Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States). Chemical Sciences Division
- Publication Date:
- Research Org.:
- Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States)
- Sponsoring Org.:
- SC-22.1 USDOE Office of Science (SC), Basic Energy Sciences (BES) (SC-22). Chemical Sciences, Geosciences & Biosciences Division; National Institutes of Health (NIH)
- OSTI Identifier:
- 1458488
- Alternate Identifier(s):
- OSTI ID: 1397624
- Grant/Contract Number:
- AC02-05CH11231; RAI087604Z
- Resource Type:
- Accepted Manuscript
- Journal Name:
- Chemico-Biological Interactions
- Additional Journal Information:
- Journal Volume: 267; Journal Issue: C; Related Information: © 2016 Elsevier Ireland Ltd; Journal ID: ISSN 0009-2797
- Publisher:
- Elsevier
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 61 RADIATION PROTECTION AND DOSIMETRY; Radionuclides; Contamination; Medical countermeasure; Chelation therapy; Prophylaxis
Citation Formats
An, Dahlia D., Kullgren, Birgitta, Jarvis, Erin E., and Abergel, Rebecca J. From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents. United States: N. p., 2016.
Web. doi:10.1016/j.cbi.2016.03.034.
An, Dahlia D., Kullgren, Birgitta, Jarvis, Erin E., & Abergel, Rebecca J. From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents. United States. https://doi.org/10.1016/j.cbi.2016.03.034
An, Dahlia D., Kullgren, Birgitta, Jarvis, Erin E., and Abergel, Rebecca J. Thu .
"From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents". United States. https://doi.org/10.1016/j.cbi.2016.03.034. https://www.osti.gov/servlets/purl/1458488.
@article{osti_1458488,
title = {From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents},
author = {An, Dahlia D. and Kullgren, Birgitta and Jarvis, Erin E. and Abergel, Rebecca J.},
abstractNote = {The potential consequences of a major radiological event are not only large-scale external radiation exposure of the population, but also uncontrolled dissemination of, and internal contamination with, radionuclides. When planning an emergency response to radiological and nuclear incidents, one must consider the need for not only post-exposure treatment for contaminated individuals, but also prophylactic measures to protect the workforce facing contaminated areas and patients in the aftermath of such events. In addition to meeting the desired criteria for post-exposure treatments such as safety, ease of administration, and broad-spectrum efficacy against multiple radionuclides and levels of challenge, ideal prophylactic countermeasures must include rapid onset; induce minimal to no performance-decrementing side effects; be compatible with current military Chemical, Biological, Radiological, Nuclear, and Explosive countermeasures; and require minimal logistical burdens. Hydroxypyridinone-based actinide decorporation agents have shown the most promise as decorporation strategies for various radionuclides of concern, including the actinides plutonium and americium. The studies here probe the extent of plutonium decorporation efficacy for two chelating agents, 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO), from early pre-exposure time points to a delay of up to 7 days in parenteral or oral treatment administration, i.e., well beyond the initial hours of emergency response. Despite delayed treatment after a contamination event, both ligands clearly enhanced plutonium elimination through the investigated 7-day post-treatment period. In addition, a remarkable prophylactic efficacy was revealed for 3,4,3-LI(1,2-HOPO) with treatment as early as 48 h before the plutonium challenge. This work provides new perspectives in the indication and use of experimental actinide decorporation treatments.},
doi = {10.1016/j.cbi.2016.03.034},
journal = {Chemico-Biological Interactions},
number = C,
volume = 267,
place = {United States},
year = {2016},
month = {3}
}
Web of Science
Figures / Tables:

Works referenced in this record:
A Public Health Perspective on the U.S. Response to the Fukushima Radiological Emergency
journal, January 2015
- Whitcomb, Robert C.; Ansari, Armin J.; Buzzell, Jennifer J.
- Health Physics, Vol. 108, Issue 3
Radiation Drugs-A Hot Topic: Radiation Drugs
journal, August 2012
- Moos, Walter H.; Shankar, Gita N.
- Drug Development Research, Vol. 73, Issue 5
Use of DTPA for Increasing the Rate of Elimination of Plutonium-238 and Americium-241 from Rodents after their Inhalation as the Nitrates
journal, November 1985
- Stather, J. W.; Stradling, G. N.; Gray, S. A.
- Human Toxicology, Vol. 4, Issue 6
Medical Countermeasures against Nuclear Threats: Radionuclide Decorporation Agents
journal, October 2008
- Cassatt, David R.; Kaminski, Joseph M.; Hatchett, Richard J.
- Radiation Research, Vol. 170, Issue 4
Treatment of human contamination with plutonium and americium: would orally administered Ca- or Zn-DTPA be effective?
journal, June 2007
- Taylor, D. M.; Hodgson, S. A.; Stradling, N.
- Radiation Protection Dosimetry, Vol. 127, Issue 1-4
Treatment of actinide exposures: a review of Ca-DTPA injections inside CEA-COGEMA plants
journal, June 2007
- Grappin, L.; Berard, P.; Menetrier, F.
- Radiation Protection Dosimetry, Vol. 127, Issue 1-4
Action of DTPA on Hepatic Plutonium: III. Evidence for a Direct Chelation Mechanism for DTPA-Induced Excretion of Monomeric Plutonium into Rat Bile
journal, October 1979
- Bhattacharyya, M. H.; Peterson, D. P.
- Radiation Research, Vol. 80, Issue 1
238 Pu elimination profiles after delayed treatment with 3,4,3LI(1,2HOPO) in female and male Swiss-Webster mice
journal, August 2014
- An, Dahlia D.; Villalobos, Jonathan A.; Morales-Rivera, Joel A.
- International Journal of Radiation Biology, Vol. 90, Issue 11
Lauriston s. Taylor Lecture: the Quest for Therapeutic Actinide Chelators
journal, January 2008
- Durbin, Patricia W.
- Health Physics, Vol. 95, Issue 5
Actinide chelation: biodistribution and in vivo complex stability of the targeted metal ions
journal, October 2012
- Kullgren, Birgitta; Jarvis, Erin E.; An, Dahlia D.
- Toxicology Mechanisms and Methods, Vol. 23, Issue 1
Biomimetic Actinide Chelators: an Update on the Preclinical Development of the Orally Active Hydroxypyridonate Decorporation Agents 3,4,3-Li(1,2-Hopo) and 5-Lio(Me-3,2-Hopo)
journal, January 2010
- Abergel, Rebecca J.; Durbin, Patricia W.; Kullgren, Birgitta
- Health Physics, Vol. 99, Issue 3
Significance of Single Variables in Defining Adequate Animal Models to Assess the Efficacy of New Radionuclide Decorporation Agents: Using the Contamination Dose as an Example: Animal Models for Chelating Agents Efficacy
journal, August 2012
- Jarvis, Erin E.; An, Dahlia D.; Kullgren, Birgitta
- Drug Development Research, Vol. 73, Issue 5
Dose-Dependent Efficacy and Safety Toxicology of Hydroxypyridinonate Actinide Decorporation Agents in Rodents: Towards a Safe and Effective Human Dosing Regimen
journal, February 2013
- Bunin, Deborah I.; Chang, Polly Y.; Doppalapudi, Rupa S.
- Radiation Research, Vol. 179, Issue 2
Gross Composition and Plasma and Extracellular Water Volumes of Tissues of a Reference Mouse
journal, January 1992
- Durbin, P. W.; Jeung, N.; Kullgren, B.
- Health Physics, Vol. 63, Issue 4
Structure of a Single Model to Describe Plutonium and Americium Decorporation by dtpa Treatments
journal, January 2010
- Fritsch, P.; Sérandour, A. L.; Grémy, O.
- Health Physics, Vol. 99, Issue 4
Biodistribution of the Multidentate Hydroxypyridinonate Ligand [ 14 C]-3,4,3-LI(1,2-HOPO), a Potent Actinide Decorporation Agent : BIODISTRIBUTION OF 3,4,3-LI(1,2-HOPO)
journal, April 2015
- Choi, Taylor A.; Endsley, Aaron N.; Bunin, Deborah I.
- Drug Development Research, Vol. 76, Issue 3
In Vitro Metabolism and Stability of the Actinide Chelating Agent 3,4,3-LI(1,2-HOPO)
journal, May 2015
- Choi, Taylor A.; Furimsky, Anna M.; Swezey, Robert
- Journal of Pharmaceutical Sciences, Vol. 104, Issue 5
Simplified Structure of a New Model to Describe Urinary Excretion of Plutonium after Systemic, Liver or Pulmonary Contamination of Rats Associated with Ca-DTPA Treatments
journal, June 2009
- Fritsch, P.; Sérandour, A. L.; Grémy, O.
- Radiation Research, Vol. 171, Issue 6
Development of the Plutonium-DTPA Biokinetic Model
journal, January 2015
- Konzen, Kevin; Brey, Richard
- Health Physics, Vol. 108, Issue 6
Works referencing / citing this record:
Simple measurement of actinides in urine using solid-state scintillation
journal, July 2019
- Janda, Jiri; Nemec, Mojmir
- Journal of Radioanalytical and Nuclear Chemistry, Vol. 322, Issue 3
Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents
journal, March 2018
- Rees, Julian A.; Deblonde, Gauthier J. -P.; An, Dahlia D.
- Scientific Reports, Vol. 8, Issue 1
Structural and thermodynamic investigation of An IV LI(O)HOPO
journal, January 2017
- Aupiais, J.; Younes, A.; Moisy, P.
- New Journal of Chemistry, Vol. 41, Issue 19
Transforming lanthanide and actinide chemistry with nanoparticles
journal, January 2020
- Pallares, Roger M.; Abergel, Rebecca J.
- Nanoscale, Vol. 12, Issue 3
Inducing selectivity and chirality in group IV metal coordination with high-denticity hydroxypyridinones
journal, January 2019
- Deblonde, Gauthier J. -P.; Lohrey, Trevor D.; Abergel, Rebecca J.
- Dalton Transactions, Vol. 48, Issue 23
Multiple Patients With Burn Injury Induced by a Chemical Explosion Managed by Physician-Staffed Helicopters
journal, January 2019
- Kondo, Akihiko; Jitsuiki, Kei; Osaka, Hiromichi
- Disaster Medicine and Public Health Preparedness, Vol. 13, Issue 4
Toxic heavy metal – Pb, Cd, Sn – complexation by the octadentate hydroxypyridinonate ligand archetype 3,4,3-LI(1,2-HOPO)
journal, January 2018
- Deblonde, Gauthier J. -P.; Lohrey, Trevor D.; An, Dahlia D.
- New Journal of Chemistry, Vol. 42, Issue 10
Figures / Tables found in this record: